Literature DB >> 33632199

Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.

Lijuan Wang1, Shucheng Pan1, Binbin Zhu1, Zhenliang Yu1, Wei Wang2.   

Abstract

BACKGROUND: The tumorigenesis of prostate cancer involves genetic mutations. Tumour mutational burden (TMB) is an emerging biomarker for predicting the efficacy of immunotherapy.
RESULTS: Single-nucleotide polymorphisms were the most common variant type, and C>T transversion was the most commonly presented type of single-nucleotide variant. The high-TMB group had lower overall survival (OS) than the low-TMB group. TMB was associated with age, T stage and N stage. Functional enrichment analysis of differentially expressed genes (DEGs) showed that they are involved in pathways related to the terms spindle, chromosomal region, nuclear division, chromosome segregation, cell cycle, oocyte meiosis and other terms associated with DNA mutation and cell proliferation. Six hub genes, PLK1, KIF2C, MELK, EXO1, CEP55 and CDK1, were identified. All the genes were associated with disease-free survival, and CEP55 and CDK1 were associated with OS.
CONCLUSIONS: The present study provides a comprehensive analysis of the significance of TMB and DEGs and infiltrating immune cells related to TMB, which provides helpful information for exploring the significance of TMB in prostate cancer.

Entities:  

Keywords:  Clinical; Gene; Prostate cancer; Tumour mutational burden

Mesh:

Year:  2021        PMID: 33632199      PMCID: PMC7905899          DOI: 10.1186/s12894-021-00795-7

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  28 in total

1.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

2.  ATM activation is accompanied with earlier stages of prostate tumorigenesis.

Authors:  Catherine Fan; Rebecca Quan; Xinchang Feng; Aubrey Gillis; Lizhi He; Edward D Matsumoto; Sam Salama; Jean-Claude Cutz; Anil Kapoor; Damu Tang
Journal:  Biochim Biophys Acta       Date:  2006-08-24

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

4.  Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.

Authors:  Nihal Ahmad
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

5.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Authors:  Chuandong Geng; Bin He; Limei Xu; Christopher E Barbieri; Vijay Kumar Eedunuri; Sue Anne Chew; Martin Zimmermann; Richard Bond; John Shou; Chao Li; Mirjam Blattner; David M Lonard; Francesca Demichelis; Cristian Coarfa; Mark A Rubin; Pengbo Zhou; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-04       Impact factor: 11.205

6.  Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.

Authors:  Chuanjie Zhang; Zongtai Li; Feng Qi; Xin Hu; Jun Luo
Journal:  Ann Transl Med       Date:  2019-11

7.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

8.  SPOP mutation leads to genomic instability in prostate cancer.

Authors:  Gunther Boysen; Christopher E Barbieri; Davide Prandi; Mirjam Blattner; Sung-Suk Chae; Arun Dahija; Srilakshmi Nataraj; Dennis Huang; Clarisse Marotz; Limei Xu; Julie Huang; Paola Lecca; Sagar Chhangawala; Deli Liu; Pengbo Zhou; Andrea Sboner; Johann S de Bono; Francesca Demichelis; Yariv Houvras; Mark A Rubin
Journal:  Elife       Date:  2015-09-16       Impact factor: 8.140

9.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

10.  Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.

Authors:  Zijian Liu; Jingshu Meng; Xiaoqian Li; Fang Zhu; Tao Liu; Gang Wu; Liling Zhang
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

View more
  7 in total

Review 1.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

2.  Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer.

Authors:  Nelson K Y Wong; Xin Dong; Yen-Yi Lin; Hui Xue; Rebecca Wu; Dong Lin; Colin Collins; Yuzhuo Wang
Journal:  Cells       Date:  2022-05-05       Impact factor: 7.666

3.  Drug Repurposing of Pantoprazole and Vitamin C Targeting Tumor Microenvironment Conditions Improves Anticancer Effect in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Zhoulei Li; Peng He; Yali Long; Gang Yuan; Wanqing Shen; Zhifeng Chen; Bing Zhang; Yue Wang; Dianchao Yue; Christof Seidl; Xiangsong Zhang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

4.  The impact of radiation therapy on the TCR Vβ chain repertoire in patients with prostate cancer.

Authors:  Maria Goulielmaki; Nikolaos Davanos; Paraskevi Kogionou; Panagiota Batsaki; Savvas Stokidis; Maria Adamaki; Eftychia Mosa; Evanthia Vasilakou; Charalambos Zambatis; Angelos D Gritzapis; Vassilios Zoumpourlis; Constantin N Baxevanis; Sotirios P Fortis
Journal:  Int J Oncol       Date:  2022-04-21       Impact factor: 5.884

5.  Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.

Authors:  Juan He; Zhen Zeng; Yuelong Wang; Jiaojiao Deng; Xin Tang; Fujun Liu; Jianhan Huang; Hongxu Chen; Ruichao Liang; Xin Zan; Zhiyong Liu; Aiping Tong; Gang Guo; Jianguo Xu; Xiaofeng Zhu; Liangxue Zhou; Yong Peng
Journal:  Mol Cancer       Date:  2021-12-18       Impact factor: 27.401

6.  Clinicopathological Significance of AKT1 and PLK1 Expression in Oral Squamous Cell Carcinoma.

Authors:  Er-Can Sun; Shuang-Shuang Dong; Zhi-Jun Li; Chang-Xue Li
Journal:  Dis Markers       Date:  2022-06-17       Impact factor: 3.464

7.  DNA methylation variation along the cancer epigenome and the identification of novel epigenetic driver events.

Authors:  Richard Heery; Martin H Schaefer
Journal:  Nucleic Acids Res       Date:  2021-12-16       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.